You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
信立泰(002294.SZ):獲得鹼基編輯藥物YOLT-101獨家許可權益
格隆匯 08-26 19:17

格隆匯8月26日丨信立泰(002294.SZ)公佈,為進一步探索、籌備創新技術和豐富公司在慢病領域的創新產品管線規劃,深圳信立泰藥業股份有限公司擬與堯唐(上海)生物科技有限公司(下稱“堯唐生物”)簽訂協議,獲得堯唐生物擁有的在研PCSK9靶點的鹼基編輯藥物“YOLT-101”的原料藥及製劑相關知識產權、技術信息(下稱“許可產品”或“YOLT-101”)於中國大陸區域的獨家許可權益,包括但不限於研發、註冊、生產、商業化銷售等。

公司將根據交易進度和研發進展情況,以自籌資金付款,其中,首付款及研發里程碑款總金額最高不超過20,500萬元。如該產品獲批上市銷售,若產品淨銷售額(以連續12個月計)首次達到協議約定數額,公司支付銷售里程碑款,銷售里程碑累計最高不超過83,000萬元。同時,在協議約定期限內,公司根據會計年度淨銷售額按一定比例支付堯唐生物銷售提成。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account